Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objective of the study was to determine whether GR haplotype 3 is associated with HF and whether this association is explained by low-grade inflammation (C-reactive protein).
|
20371666 |
2010 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Other predictors included ischemic etiology (HR 1.33, p=0.023), prior hospitalization for heart failure (HR 1.34, p=0.017), C-reactive protein (HR 1.04, p<0.001), and statin use (HR 0.70, p=0.016).
|
29169753 |
2018 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We collected conventional (blood pressure, cholesterol, adiposity), lifestyle, and novel (C-reactive protein, CRP) risk factors at baseline in participants from the Scottish Health Surveys (n = 5946, 44.5% men, aged 53.6 +/- 12.4 years), who were followed up over an average of 7.1 years for cardiovascular disease (CVD) events (a composite of fatal and nonfatal events incorporating acute myocardial infarction, coronary artery bypass surgery, percutaneous coronary angioplasty, stroke, heart failure).
|
19587606 |
2009 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, temporal changes in CRP levels were associated with cancer death in the overall cohort; HF patients with CRP ≥ 2.0 mg/L at both baseline and 1-year had significantly increased cancer death, while those with CRP ≥ 2.0 mg/L at baseline and < 2.0 mg/L at 1-year not.
|
31104823 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the predictive value of single and repeated measurements of GDF-15 compared to Cystatin C and CRP for incidence of heart failure (HF) and death due to coronary heart disease (CHD) in the general population.
|
29771963 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further analysis revealed that MedDietScore differentially affected patients' prognosis according to heart failure phenotype, with short-term impact in HFrEF and HFmrEF patients yet longer positive outcomes in HFpEF and C-reactive protein potentially mediated these relations.
|
28832572 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Longitudinal patterns of N-terminal pro B-type natriuretic peptide, troponin T, and C-reactive protein in relation to the dynamics of echocardiographic parameters in heart failure patients.
|
31596459 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Older age, atrial fibrillation, hypertension, obesity, edema, high C-reactive protein, and smoking were risk factors for HF.
|
29934374 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Women had a lower risk for HF than men.Sex differences were seen for systolic blood pressure, heart rate, CRP, and NT-proBNP, with a lower HF risk in women.
|
30819375 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
High-sensitivity C-reactive protein in chronic heart failure: patient characteristics, phenotypes, and mode of death.
|
31350553 |
2020 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum C-reactive protein (CRP) elevation is associated with poor clinical outcome in patients with heart failure (HF).
|
22875408 |
2013 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum C-reactive protein (CRP) elevation predicts the development of heart failure in patients with hypertension.
|
21220701 |
2011 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Several factors were associated with positive D-dimer results potentially falsely indicating thromboembolic disease in multivariate analysis including advanced age (odds ratio [OR] 1.04, 95% confidence interval [CI] 1.04-1.05, p < 0.001), congestive heart failure (CHF) (OR 2.79, 95% CI 1.77-4.4, p < 0.01), renal failure (OR 2.00, 95% CI 1.23-3.24, p = 0.005), history of malignancy (OR 2.6, 95% CI 1.57-4.31, p < 0.001), C-reactive protein (CRP) (OR 1.02, 95% CI 1.01-1.02, p < 0.001) and glomerular filtration rate (GFR) (OR 0.99, 95% CI 0.99-1.00, p = 0.003).
|
31339853 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Were performed quality of life (Minnesota Living with Heart Failure Questionnaire-MLHFQ) and sleep questionnaires (Epworth, Pittsburgh Sleep Quality Index-PSQI), serum B-type natriuretic peptide (BNP), serum C-reactive protein, transthoracic echocardiography, cardiopulmonary exercise test and overnight polysomnography immediately before and six months after pericardiectomy.
|
31603935 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the multivariable analysis, the independent predictors of death were age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.02-1.13), C-reactive protein (CRP) at hospital admission (OR 1.12, 95% CI 1.04-1.21), length of the vegetation at diagnosis (OR 1.15, 95% CI 1.03-1.28), development of heart failure (OR 6.43, 95% CI 2.14-19.33), and embolic events during antimicrobial therapy (OR 12.14, 95% CI 2.11-71.89).
|
29382606 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We undertook metabolomic and lipidomic phenotyping of a cohort of heart failure (HF) patients and utilized Multiple Regression Analysis (MRA) to identify associations to CPET and HFBio test performance (peak oxygen consumption (Peak VO2), oxygen uptake efficiency slope (OUES), exercise duration, and minute ventilation-carbon dioxide production slope (VE/VCO2 slope), as well as the established HF biomarkers of inflammation C-reactive protein (CRP), beta-galactoside-binding protein (galectin-3), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP)).
|
31220103 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Presence of metabolic syndrome (MS) and its components, presence of heart failure, severity of CAD symptoms, severe past ventricular arrhythmia (sustained ventricular tachycardia [sVT] or ventricular fibrillation [VF]), lower left ventricle ejection fraction, higher left ventricle mass index, higher end-diastolic volume and higher number of smoking pack-years were significantly associated with higher WBC, CRP and IL-6.
|
26864064 |
2016 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study examined the individual and combined effect of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), interleukin-6 (IL-6), and hs-CRP on the prediction of heart failure incidence or progression in patients with type 2 diabetes.
|
28684396 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Gold-nanorod enhances dielectric voltammetry detection of c-reactive protein: A predictive strategy for cardiac failure.
|
30716591 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study we investigated distribution of CRP, the Terminal Complement Complex (C5b-9) and macrophages (CD68) in the myocardium of patients suffering from non-ischaemic heart failure and their implication on clinical parameters.
|
19343415 |
2009 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the multivariable analysis, higher vWF concentrations (middle tertile hazard ratio [HR] 4.59, 95% confidence interval [CI] 1.55-13.50 [P=0.006]; upper tertile HR 4.10, 95% CI 1.43-11.75 [P=0.009]), age≥75years (HR 5.02, 95% CI 1.53-16.49; P=0.008), heart failure (HR 2.05, 1.01-4.19; P=0.048), C-reactive protein, log<sub>2</sub> per unit increase (HR 1.29, 95% CI 1.04-1.61; P=0.021), no warfarin at discharge (HR 4.96, 95% CI 2.02-12.20; P<0.0001) and no aspirin at discharge (HR 4.41, 95% CI 1.71-11.97; P=0.002) were independently associated with an increased risk of stroke and all-cause death, whereas female sex was a protective factor (HR 0.35, 0.16-0.78; P=0.01).
|
29685722 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concerning death due to heart failure, NT-proBNP was associated with an 8-fold and C-reactive protein, GDF-15, and cystatin-C, with a 3-fold increase in risk.
|
30427997 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Age, chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), forced expiratory volume in one second/ forced vital capacity (FEV1/FVC) ratio, duration of operation, hemoglobin, albumin and C-reactive protein (CRP) were potential risk factors for PPCs by univariate analysis.
|
30003856 |
2018 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
After further adjustment for biomarkers (high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A<sub>2</sub> activity, high-sensitivity troponin I, and B-type natriuretic peptide), IL-6 remained significantly associated with the risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09-1.88) and cardiovascular death or heart failure (adj HR 1.79, 95% CI 1.22-2.63).
|
29066436 |
2017 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Efficient electron-mediated electrochemical biosensor of gold wire for the rapid detection of C-reactive protein: A predictive strategy for heart failure.
|
31400725 |
2019 |